1. EST64454: a Highly Soluble σ 1 Receptor Antagonist Clinical Candidate for Pain Management.
- Author
-
Díaz JL, García M, Torrens A, Caamaño AM, Enjo J, Sicre C, Lorente A, Port A, Montero A, Yeste S, Álvarez I, Martín M, Maldonado R, de la Puente B, Vidal-Torres A, Cendán CM, Vela JM, and Almansa C
- Subjects
- Analgesics chemical synthesis, Analgesics pharmacokinetics, Animals, Caco-2 Cells, Humans, Mice, Molecular Structure, Piperazines chemical synthesis, Piperazines pharmacokinetics, Pyrazoles chemical synthesis, Pyrazoles pharmacokinetics, Rats, Wistar, Structure-Activity Relationship, Sigma-1 Receptor, Analgesics therapeutic use, Pain drug therapy, Piperazines therapeutic use, Pyrazoles therapeutic use, Receptors, sigma antagonists & inhibitors
- Abstract
The synthesis and pharmacological activity of a new series of pyrazoles that led to the identification of 1-(4-(2-((1-(3,4-difluorophenyl)-1 H -pyrazol-3-yl)methoxy)ethyl)piperazin-1-yl)ethanone ( 9k , EST64454) as a σ
1 receptor (σ1 R) antagonist clinical candidate for the treatment of pain are reported. The compound 9k is easily obtained through a five-step synthesis suitable for the production scale and shows an outstanding aqueous solubility, which together with its high permeability in Caco-2 cells will allow its classification as a BCS class I compound. It also shows high metabolic stability in all species, linked to an adequate pharmacokinetic profile in rodents, and antinociceptive properties in the capsaicin and partial sciatic nerve ligation models in mice.- Published
- 2020
- Full Text
- View/download PDF